Skip to content

Why This Hong Kong Tycoon’s Family Backed Biotech Firm Ditches the City for Nasdaq Listing

Loeb & Loeb Partner Lewis Ho is quoted on how China’s pharmaceutical pricing reforms have led to delays in biotech IPO listings in Hong Kong.

Click here to read the article on South China Morning Post’s website. This article also appeared in The Street and Yahoo! News